Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18910549 | Humanized Anti-DNAM-1 Antibody | October 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18747102 | MULTIVALENT AND BISPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | June 2024 | March 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18023701 | ANTI-VEGF-ANTI-PD-L1 BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION OF SAME, AND USES THEREOF | February 2023 | April 2025 | Allow | 25 | 1 | 0 | No | No |
| 18006189 | GP130 Binding Molecules and Methods of Use | January 2023 | July 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17993502 | METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | November 2022 | June 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17937666 | COMPOSITION OF HUMAN RECOMBINANT ANTIBODY FRAGMENTS THAT COMPLETELY NEUTRALIZE THE VENOM OF THE SCORPION CENTRUROIDES SCULPTURATUS | October 2022 | December 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17845742 | Antibodies Binding to ILT4 | June 2022 | June 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17642171 | ANTI-PD-L1 SINGLE-DOMAIN ANTIBODY AND DERIVATIVES AND USE THEREOF | March 2022 | June 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17682082 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | February 2022 | May 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17667349 | STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS | February 2022 | February 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17532688 | METHOD OF INDUCING ANTIGEN-SPECIFIC TOLERANCE IN A SUBJECT BY ADMINISTERING A COMPOSITION COMPRISING AN APOPTOTIC BODY SURROGATE AND COUPLED IMMUNODOMINANT ANTIGENIC EPITOPES ASSOCIATED WITH AUTOIMMUNE DISEASE | November 2021 | February 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17525673 | MONOCYTE COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIOUS DISEASE | November 2021 | August 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17440836 | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF | September 2021 | November 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17421334 | CROSS SPECIES SINGLE DOMAIN ANTIBODIES TARGETING MESOTHELIN FOR TREATING SOLID TUMORS | July 2021 | August 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17268915 | T CELL RECEPTOR CONSTRUCTS AND USES THEREOF | June 2021 | February 2025 | Allow | 48 | 1 | 0 | No | No |
| 17418681 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING ATHEROSCLEROSIS | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17418768 | Anti-PD-L1 Binding Proteins and Methods of Use Thereof | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17418764 | Anti-PD-1 Binding Proteins and Methods of Use Thereof | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17417686 | MONOCLONAL ANTIBODIES AGAINST THE BETA CHAIN REGION OF HUMAN TRBV9 | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17413360 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND IDENTIFYING TARGETS THEREFORE | June 2021 | April 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17312747 | TREM2 ANTIBODIES AND USES THEREOF | June 2021 | February 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17311114 | COMBINATIONAL TCR-T CELL THERAPY TARGETING TUMOR ANTIGENS, TGF-BETA, AND IMMUNE CHECKPOINTS | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17335677 | MODIFIED MEMBRANE SPANNING PROTEINS AND METHODS FOR THE PREPARATION AND USE THEREOF | June 2021 | May 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17288600 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING T CELL-DRIVEN DISEASES | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17288273 | Novel Rationally Designed Protein Compositions | April 2021 | April 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17288139 | FORMULATIONS COMPRISING A TRIS BUFFER AND A PROTEIN | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17288485 | HEAVY CHAIN ANTIBODIES BINDING TO CD38 | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17283292 | CONFORMATION-SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF | April 2021 | February 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17283128 | ANTIBODIES TARGETING CD137 AND METHODS OF USE THEREOF | April 2021 | September 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17280246 | NEOANTIGEN COMPOSITIONS; AND METHODS OF PREPARATION AND USE THEREOF | March 2021 | March 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17278345 | Antibody against human cardiac troponin I and use thereof | March 2021 | September 2024 | Allow | 42 | 1 | 1 | No | No |
| 17276796 | CONDITIONALLY ACTIVATED TARGET-BINDING MOLECULES | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17274746 | Anti-IL4 Receptor Antibodies for Veterinary Use | March 2021 | March 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17274458 | SINGLE-DOMAIN ANTIBODIES AGAINST CD33 AND CONSTRUCTS THEREOF | March 2021 | January 2025 | Allow | 46 | 2 | 1 | No | No |
| 17273965 | TREATMENT AND PREVENTION OF HEMOPHILIC ARTHROPATHY WITH AN ANTIBODY AGAINST ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) | March 2021 | February 2025 | Allow | 47 | 3 | 0 | Yes | No |
| 17273753 | HUMANIZED ANTI-C5 ANTIBODIES AND USES THEREOF | March 2021 | May 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17270323 | IMMUNOTHERAPY WITH METABOLIC ENZYME EXPRESSION | February 2021 | February 2025 | Allow | 48 | 1 | 0 | No | No |
| 17268933 | CATABODIES AND METHODS OF USE THEREOF | February 2021 | January 2025 | Allow | 47 | 1 | 1 | No | No |
| 17266356 | COMBINATION THERAPIES COMPRISING PD-1-BASED CHIMERIC PROTEINS | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17266419 | HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF | February 2021 | February 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17266015 | COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17250443 | ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE | January 2021 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17260398 | THERAPEUTIC COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY | January 2021 | April 2025 | Allow | 51 | 4 | 1 | Yes | No |
| 17259584 | MART-1(27-35) EPITOPE-SPECIFIC T CELL RECEPTOR | January 2021 | June 2024 | Allow | 42 | 1 | 1 | No | No |
| 16955197 | ANTIBODIES TO ICOS | June 2020 | December 2024 | Allow | 54 | 1 | 1 | Yes | No |
| 16759937 | ANTIBODIES TO alpha-SYNUCLEIN AND USES THEREOF | April 2020 | March 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16753488 | ANTI-IL-5RAlpha MONOCLONAL ANTIBODY | April 2020 | August 2024 | Allow | 52 | 2 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MELCHIOR, JAMES RYLAND works in Art Unit 1644 and has examined 45 patent applications in our dataset. With an allowance rate of 66.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner MELCHIOR, JAMES RYLAND's allowance rate of 66.7% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MELCHIOR, JAMES RYLAND receive 1.07 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MELCHIOR, JAMES RYLAND is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +68.2% benefit to allowance rate for applications examined by MELCHIOR, JAMES RYLAND. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.